MedTrace Logo

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

NCT00330044 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-05-02

No results posted yet for this study

Summary

To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer

Conditions

  • Inoperable Non Small Cell Lung Cancer

Interventions

DRUG

Premetrexed (Alimta)

DRUG

Carboplatin

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Maria Werner-Wasik, MD · Thomas Jefferson University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-08-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330044 on ClinicalTrials.gov